Key points are not available for this paper at this time.
Design
Editorial
Answers are grounded in this paper and cite their sources.
This editorial discusses the historical context and clinical translation of pacing therapy for atrioventricular dromotropathy (long PR syndrome) and cardiac resynchronization therapy.
This editorial refers to ‘Pacing therapy for atrioventricular dromotropathy: a combined computational experimental-clinical study’, by Salden F. et al., pp. 784--795. The story repeats itself. In 2009, David A. Kass a pioneer in experimental cardiac resynchronization therapy (CRT) research, said: ‘Remarkably, CRT was mostly developed and tested in patients first, and the speed at which the concept was translated to an approved clinical therapy was unusually quick’.1 Indeed, few years have elapsed between the first clinical report by Cazeau et al.2 and clinical recommendations in international guidelines.3 In the meantime, randomized clinical trials, MUSTIC and MIRACLE, in particular, provided evidence of clinical efficacy. Animal experiments came later and allowed ‘understanding how CRT works at the molecular and cellular levels’.1 The story was nearly similar for pacing therapy in long PR syndrome. In the early 90s, observational data suggested that by solely correcting major atrioventricular (AV) dyssynchrony,...
No takes yet. Share an insight, caveat, or question.
Galand et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: